Key result
The O3039 vaccine strain, alone or combined with O1 Manisa, effectively protected cattle against the O/ME-SA/Ind/2001d FMD virus lineage at 7 and 21 days post-vaccination.
Why the study?
The emerging O/ME-SA/Ind-2001 lineage of foot-and-mouth disease virus showed a poor match with the widely used O1 Manisa vaccine strain, requiring evaluation of alternative vaccine strains.
Does the O3039 vaccine strain protect cattle against heterologous challenge with the O/ME-SA/Ind2001d FMD virus lineage?
Does the O3039 vaccine strain protect cattle against heterologous challenge with the O/ME-SA/Ind2001d FMD virus lineage?
The O3039 FMD vaccine strain provides effective emergency protection in cattle against the emerging O/ME-SA/Ind-2001d lineage.
Answers are grounded in this paper and cite their sources.
Limited FMD vaccine strains restrict outbreak control; leaves open rapid efficacy testing against emerging variants.
Vaccination is one of the best approaches to control and eradicate foot-and-mouth disease (FMD). To achieve this goal, vaccines with inactivated FMD virus antigen in suitable adjuvants are being used in addition to other control measures. However, only a limited number of vaccine strains are commercially available, which often have a restricted spectrum of activity against the different FMD virus strains in circulation. As a result, when new strains emerge, it is important to measure the efficacy of the current vaccine strains against these new variants. This is important for countries where FMD is endemic but also for countries that hold an FMD vaccine bank, to ensure they are prepared for emergency vaccination. The emergence and spread of the O/ME-SA/Ind-2001 lineage of viruses posed a serious threat to countries with OIE-endorsed FMD control plans who had not reported FMD for many years. In vitro vaccine-matching results showed a poor match (r1-value < 0.3) with the more widely used vaccine strain O1 Manisa and less protection in a challenge test. This paper describes the use of the O3039 vaccine strain as an alternative, either alone or in combination with the O1 Manisa vaccine strain with virulent challenge by a O/ME-SA/Ind-2001d sub-lineage virus from Algeria (O/ALG/3/2014). The experiment included challenge at 7 days post-vaccination (to study protection and emergency use) and 21 days post-vaccination (as in standard potency studies). The results indicated that the O3039 vaccine strain alone, as well as the combination with O1 Manisa, is effective against this strain of the O/ME-SA/Ind/2001d lineage, offering protection from clinical disease even after 7 days post-vaccination with a reduction in viraemia and virus excretion.
No takes yet. Share an insight, caveat, or question.
Nagendrakumar B. Singanallur (2021) studied Foot-and-mouth disease (FMD). O3039 vaccine strain alone or in combination with O1 Manisa vaccine strain was evaluated on Protection from clinical disease, reduction in viraemia and virus excretion. The O3039 vaccine strain, alone or combined with O1 Manisa, effectively protected cattle against the O/ME-SA/Ind/2001d FMD virus lineage at 7 and 21 days post-vaccination.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: